Last updated: February 15, 2026
What is the drug associated with NDC 44523-0410?
The National Drug Code (NDC) 44523-0410 corresponds to Multaq (dronedarone), produced by Sanofi. Dronedarone is an anti-arrhythmic agent indicated for the reduction of hospitalization due to atrial fibrillation/flutter in patients with intermittent atrial fibrillation or flutter.
What is the current market landscape for dronedarone?
Market Size and Segmentation
- The global anti-arrhythmic drugs market was valued at approximately $4.7 billion in 2022.
- It is projected to reach around $6.5 billion by 2028, growing at a compound annual growth rate (CAGR) of 5.4%.
Key Players
- Sanofi (Multaq)
- Pfizer (Amiodarone)
- Teva Pharmaceuticals (Dronedarone generics)
- Bayer (Dabigatran)
Sanofi maintains a leading position with Multaq, capturing about 65% of the branded anti-arrhythmic segment, driven by its approved indication and established efficacy profile.
Regulatory and Market Access
- FDA approval for Multaq was granted in 2010.
- Market access varies based on reimbursement policies; some regions restrict use due to safety concerns.
Pricing and Reimbursement
- In the US, the average wholesale price (AWP) for Multaq runs around $20 per 60-count, 200 mg tablets.
- Insurance coverage limits out-of-pocket costs, with paid amounts generally in the $15-20 range per prescription.
- Generics entered the market post-patent expiry, reducing prices by approximately 40%-60%.
What are the key factors influencing current pricing?
- Patent Status: Multaq's patent protection expired in 2019, leading to generic entries.
- Market Competition: Generics dominate the retail segment, pushing down prices.
- Safety Profile and Indications: Safety concerns regarding hepatotoxicity and heart failure risk have impacted prescribing rates.
- Reimbursement Policies: Coverage variations influence the price patients pay and market access.
- Manufacturing Costs: Generic manufacturers benefit from lower production costs, enabling aggressive price setting.
What are the price projections for the near future?
| Year |
Branded (Multaq) Price (USD) |
Generic Price (USD) |
Market Share Estimates |
| 2023 |
$20-22 |
$12-15 |
Branded: 30%, Generics: 70% |
| 2024 |
$18-20 |
$10-13 |
Branded: decreasing, Generics dominance continues |
| 2025 |
$15-17 |
$8-11 |
Generics capture 80-85% of prescriptions |
| 2026 |
$12-14 |
$7-9 |
Further price reductions driven by competition |
Key drivers of future price trends
- Patent expirations and patent challenges will sustain lower prices.
- Increased usage of generics will suppress branded drug pricing.
- Policy shifts toward price controls may further influence affordable access.
- Ongoing safety evaluations could alter prescribing trends, affecting market volume.
Impact of regulatory changes and crises
- The US FDA's REMS (Risk Evaluation and Mitigation Strategies) with a focus on hepatic safety may restrict use and limit growth.
- The potential for new anti-arrhythmic therapies entering the market could further intensify price competition.
Summary
Dronedarone (NDC 44523-0410) faces a market characterized by declining branded pricing due to patent expiry, rising generic competition, and safety concerns. Current prices are approximately $20 for branded and $12-15 for generics per 60 tablets, with projections indicating further declines to around $8-11 for generics within three years. The dominance of generics over the coming years will likely maintain low retail price levels, with periodic adjustments influenced by safety profiles, regulatory policies, and market entry of alternative therapies.
Key Takeaways
- The market is shifting rapidly toward generics, reducing prices.
- The branded drug, Multaq, remains available but is losing market share.
- Price projections suggest a continued decline, with generics enabling more affordable treatment.
- Regulatory safety concerns and new therapies could influence future pricing and market volume.
- Price stability for generics is expected due to manufacturing efficiencies and market saturation.
FAQs
1. How does patent expiry affect dronedarone pricing?
Patent expiry allows generic manufacturers to produce and sell equivalents, decreasing prices through competition.
2. What safety concerns impact dronedarone’s market?
Potential hepatotoxicity and increased risk of heart failure restrict prescribing, which can limit market growth.
3. Are there alternative drugs to dronedarone?
Yes, including amiodarone, flecainide, and others, with varying safety profiles and indications impacting market share.
4. How are reimbursement policies influencing drug prices?
Reimbursement limits out-of-pocket costs but can also restrict access, affecting overall demand and pricing strategies.
5. What global factors could impact future prices?
Regulatory policies, market entry of new anti-arrhythmic agents, and regional safety or affordability initiatives play crucial roles.
References
- MarketWatch. “Anti-arrhythmic Drugs Market Size, Share & Trends Analysis Report, 2022-2028.”
- FDA. “FDA Approves Multaq (dronedarone) for Patients with Atrial Fibrillation.”
- IQVIA. “Pharmaceutical Market Data, 2022.”
- Sanofi. “Multaq Drug Information and Label, 2022.”
- GlobalData. “Anti-Arrhythmic Drugs Market Forecast, 2022-2028.”
